Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 1.00 |
| ▸ | PARP2 | Q9UGN5 | 5/20 | 0.93 |
| ▸ | TNKS | O95271 | 1/20 | 0.70 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.70 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.70 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 0.70 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.70 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.70 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL631124 | 0.96 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| SCHEMBL631440 | 0.89 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| SCHEMBL630681 | 0.84 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| SCHEMBL29915241 | 0.83 | PARP1 (0.85) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL29354914 | 0.82 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL5511373 | 0.82 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL422318 | 0.82 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL422320 | 0.82 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL30418660 | 0.82 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL422319 | 0.82 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1869011-B1 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH A QUATERNARY CARBON AT THE 2-POSITION ARE POTENT PARP INHIBITORS | ABBOTT LAB (US) | 2012-08-01 | — | — | EP | claimed |
| US-7550603-B2 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | ABBOTT LABORATORIES INC. (US) | 2009-06-23 | — | — | US | claimed |
| US-20060229289-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | ABBVIE INC. | 2006-10-12 | — | — | US | claimed |
| US-20160324829-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | ABBVIE INC. (US) | 2016-11-10 | — | — | US | disclosed |
| US-20150005354-A1 | Combination Therapy With Parp Inhibitors | ABBVIE INC. | 2015-01-01 | — | — | US | disclosed |
| US-20150005355-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | ABBVIE INC. | 2015-01-01 | — | — | US | disclosed |
| EP-2338487-B1 | Combination therapy with PARP inhibitors | ABBOTT LAB (US) | 2013-09-11 | — | — | EP | disclosed |
| US-20130225647-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | ABBVIE INC. (US) | 2013-08-29 | — | — | US | disclosed |
| EP-2420499-B1 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH A QUATERNARY CARBON AT THE 2-POSITION AS POTENT PARP INHIBITORS | ABBOTT LAB (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-2420234-B1 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH A QUATERNARY CARBON AT THE 2-POSITION AS PARP INHIBITORS FOR USE IN TREATING CANCER | ABBOTT LAB (US) | 2013-07-10 | — | — | EP | disclosed |
| US-20120264795-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | ABBVIE INC. | 2012-10-18 | — | — | US | disclosed |
| US-20110152336-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| EP-2329818-A1 | Combination therapy with PARP inhibitors | Abbott Laboratories (US) | 2011-06-08 | — | — | EP | disclosed |
| US-7550603-B2 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | ABBOTT LABORATORIES INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20090029966-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2009-01-29 | — | — | US | disclosed |
| US-20080293795-A1 | temozolomide and veliparib for breast cancer | ABBOTT LABORATORIES | 2008-11-27 | — | — | US | disclosed |
| US-20080280867-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080146638-A1 | primary small cell lung cancer with veliparib and temozolomide; poly/adp-ribose/polymerase (PARP) | ABBOTT LABORATORIES (US) | 2008-06-19 | — | — | US | disclosed |
| US-20070265324-A1 | Combination Therapy with Parp Inhibitors | ABBOTT LABORATORIES | 2007-11-15 | — | — | US | disclosed |
| US-20060229289-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | ABBVIE INC. | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160324829-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | PARP2, PARP1, PARP3 | PARP1 2/4885PARP2 1/4885TNKS 33/4885 |
| US-20090029966-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | PARP2, PARP1, PARP3 | PARP1 2/4885PARP2 1/4885TNKS 33/4885 |
| US-20150005354-A1 | Combination Therapy With Parp Inhibitors | PARP2, PARP1, PARP3 | PARP1 2/4885PARP2 1/4885TNKS 38/4885 |
| US-20070265324-A1 | Combination Therapy with Parp Inhibitors | PARP2, PARP1, PARP3 | PARP1 2/4885PARP2 1/4885TNKS 38/4885 |
| US-20130225647-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | PARP2, PARP1, PARP3 | PARP1 2/4885PARP2 1/4885TNKS 38/4885 |
| US-20080146638-A1 | primary small cell lung cancer with veliparib and temozolomide; poly/adp-ribose/polymerase (PARP) | PARP1, PARP2, PARP3 | PARP1 1/4885PARP2 2/4885TNKS 19/4885 |
| US-20110152336-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | PARP2, PARP1, PARP3 | PARP1 2/4885PARP2 1/4885TNKS 38/4885 |
| US-20060229289-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | PARP1, PARP2, PARP4 | PARP1 1/4885PARP2 2/4885TNKS 15/4885 |
| US-20080293795-A1 | temozolomide and veliparib for breast cancer | PARP1, PARP2, BRCA1 | PARP1 1/4885PARP2 2/4885TNKS 24/4885 |
| US-20080280867-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | PARP2, PARP1, PARP3 | PARP1 2/4885PARP2 1/4885TNKS 33/4885 |
| US-20150005355-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | PARP2, PARP1, PARP3 | PARP1 2/4885PARP2 1/4885TNKS 33/4885 |
| US-20120264795-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | PARP1, PARP2, PARP12 | PARP1 1/4885PARP2 2/4885TNKS 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.